IMPETEX ® Chlorchinaldol + Diflucortolone valerate

IMPETEX ® is a drug based on Chlorchaldol + Diflucortolone valerate

THERAPEUTIC GROUP: Active corticosteroids associated with antibiotics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications IMPETEX ® Chlorchinaldol + Diflucortolone valerate

IMPETEX ® is indicated in the treatment of cutaneous inflammatory / allergic pathologies complicated by bacterial, fungal or mixed overinfections.

Mechanism of action IMPETEX ® Chlorchinaldol + Diflucortolone valerate

The therapeutic efficacy of IMPETEX ® is evidently associated with the presence of its two active ingredients with different and complementary therapeutic activities, which make it an excellent medicinal specialty useful during inflammatory skin lesions complicated by bacterial superinfections. Indeed :

Diflucortolone valerate is a corticosteroid, generally used for topical use, endowed with a marked anti-inflammatory activity supported both by the ability to inhibit the cascade of molecular events necessary to guarantee the synthesis of inflammatory cytokines and by the ability to inhibit recall and activation. loco of cellular elements of phlogosis.
Chlorchinaldol is an antibiotic belonging to the vast family of quinolones, therefore endowed with a broad-spectrum antibiotic activity generally effective both against Gram positive and negative bacteria and some dermatophytes and yeasts.

Also in this case the mechanism of action seems related to the ability to inhibit the activity of enzymes involved in bacterial DNA replication processes. The activity of the aforementioned active principles is further optimized by the good pharmacokinetic properties which by significantly limiting the systemic absorption of the active ingredients reduce the potential side effects.

Studies carried out and clinical efficacy

DIFLUCORTOLONE / CHLORCHINALDOL IN THE TREATMENT OF INFLAMMATORY BONDS Clin Exp Dermatol. 2009 Dec; 34 (8): e611-3. doi: 10.1111 / j.1365-2230.2009.03301.x. Epub 2009 Jun 1.

Study demonstrating the efficacy of the association between Diflucortolone valerate and Chlorchinaldol in ensuring prompt remission of inflammatory lesions present in patients with diseases such as Incontinentia Pigmenti, characterized by hypereosinophilic vesicles.

ANTIMICROBIAL EFFECTIVENESS IN VITRO OF CHLORCHINALDOL Pathol Biol (Paris). 1991 Feb; 39 (2): 136-9.

Experimental study that demonstrates the efficacy of Chlorchinaldol in reducing the proliferation and vitality of microbial species such as Neisseria gonorrhea and Chlamydia Tracomatis, often causing serious clinical complications

DIFLUCORTOLONE IN THE TREATMENT OF ITCHING Mycoses. 2013 May; 56 Suppl 1: 41-3. doi: 10.1111 / myc.12058.

Clinical case demonstrating the efficacy of topical treatment with Diflucortolone valerate in ensuring a prompt remission of the complained symptomatology in a patient suffering from pruritus associated with intertrigo from Candida Albicans.

Method of use and dosage

IMPETEX ® Cream for cutaneous use with 1 g of Chlorchinaldol and 0, 1 g of Diflucortolone valerato. Dosages and timing of intake should be defined by your doctor based on the patient's clinical conditions and the therapeutic goals to be achieved. In principle, applying the appropriate quantity of cream 2-3 times a day on a thin layer seems sufficient to guarantee a prompt remission of the complained symptomatology.

Warnings IMPETEX ® Chlorchinaldol + Diflucortolone valerate

The use of IMPETEX ® should necessarily be preceded by a careful medical examination in order to clarify the origin of the lesion and any prescriptive appropriateness. As with any topical treatment with corticosteroids, even for those with IMPETEX ® it is necessary that the patient respects some simple hygienic-sanitary rules useful to limit the incidence of potential side effects and to optimize the effectiveness of the therapy itself. More precisely, the patient should avoid contact of the drug with eyes and mucous membranes, avoid extending the application to large regions, avoid prolonging the therapy beyond what is necessary, consult your doctor following the appearance of side effects and keep the drug out from the reach of children.

PREGNANCY AND BREASTFEEDING

The aforementioned contraindications to the use of IMPETEX ® also extend to pregnancy and the subsequent period of breastfeeding, given the toxic and mutagenic potential of corticosteroids for the health of the fetus and infant.

Interactions

At the present time, known pharmacological interactions are not known, although it should be remembered that the simultaneous intake of cytochrome inhibitor drugs may increase blood concentrations of the amount of corticosteroid absorbed.

Contraindications IMPETEX ® Chlorchinaldol + Diflucortolone valerate

The use of IMPETEX ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients, in patients suffering from inadequately treated viral, bacterial and fungal infections, from acne rosacea and perioral dermatitis.

Undesirable effects - Side effects

IMPETEX ® therapy could lead to the appearance of local and transient undesirable effects such as erythema, contact dermatitis, hypertrichosis, cutaneous atrophy, striae and telangiectasia. Fortunately the side effects worthy of note are rarer.